RBCC In Talks With Renowned Prospect For All-New Stem Cell Research Opportunities!
In September 2012, Rainbow Biosciences (RBCC) once again cracked open the deal pipeline by expanding the focus of culturing 3D cell clusters to include adult stem cells as well. This burgeoning field of biotechnology is pulsing with promising new technologies that could potentially save hundreds of thousands – if not millions – of lives over the course of the next five to ten years. At Rainbow Biosciences, we are dedicated to bringing new deals to the table starting with a promising stem cell target.
Adult stem cells are vital to the biotech world for two major reasons:
First, these cells can be harvested directly from the host that needs them, which means a.) There is nearly zero chance of rejection from the recipient and b.) There is abundant supply.
Second, despite black tape and controversial sentiment surrounding stem cells research in general, scientific research of adult stem cell has achieved remarkable results. Contrary to former belief, scientists now acknowledge that adult stem cells may offer the same plasticity as embryonic cells, which means adult cells may have the same potential as embryonic cells – but without the controversy.
Perpetual growth opportunities and a solid business plan – RBCC has the tools needed for early success.
A New Partnership Could Net Large Rewards
Rainbow Biosciences recognizes genetic testing as the future of medicine, and we have every intention of securing our position in the burgeoning sector by expanding and honing our genetic exploration initiatives and developments.
In the next few weeks we expect to finalize our partnership with a pioneering genome-mapping facility based in Houston, Texas. This strategic alliance will enable us to focus on cutting-edge pharmacogenomics, a field of study resulting from the Human Genome Project.
The key differences in drug metabolism and response vary from person to person, and are often rooted in the individual’s genes. In accordance with the Human Genome Project, by studying a patient’s specific genotype, doctors can eliminate the trial-and-error approach to treatment and assess genetic variations in patients in order to create optimal drug treatment plans.
Upon completing our relationship with the Houston facility, we hope to leverage our joing-venture partnership with Nano3D BioSciences (n3D) to improve the efficacy of local delivery of biologic agents and small molecules safer using the latest advances in pharmacogenomics. Pharmacogenomics is the next evolution in personalized medicine.
Invest in RBCC and you’re investing in the future of stem cell research industry
What's Happening In The Biosciences Industry?
- Celgene Corp. has agreed to invest $20 million to extend an exclusive partnership with private drug maker Agios Pharmaceuticals. The company received a $130 million upfront payment, including an equity investment to develop a novel class of cancer drugs that inhibit cancer cells from feeding themselves.
- U.S. Food and Drug Administration approvals recently reached a 15-year high, according to Bloomberg. In 2012 alone the FDA approved 39 novel medicines, a 30% increase compared to the number of approvals for 2011. In the last decade, the number of FDA approvals averaged approximately 23 a year.
- The FDA’s new “breakthrough designation” allows new drug candidates to be approved after a single round of testing vs. the usual three – this designation is in addition to agency’s three other programs designed to bring crucial new drugs to market in a shorter time frame: Fast Track, Priority Review, Accelerated Approval.
- In recent years the FDA has accelerated its review process for medical products to help speed the availability of new treatments to patients. The average review time for an innovative new drug is only six months, and in some cases, less.
EDGAR & XBRL Files
RBCC: Breakthrough Innovations Mean Big Returns
The market for bioscience is booming - the biotech sector alone saw $25 billion in profits in 2010, a 15% jump from the previous record set in 2007. The genetic testing sector, which Rainbow Biosciences is now heavily involved in, is one of the fastest-growing segments of the global biotech industry and is forecast to reach $2.2 billion by 2017!
Rainbow Biosciences is on a mission to play a leading role in the quest for a breakthrough, advancing on our progress to deliver better treatments and potential cures through aggressive research and innovation.
Join RBCC in its endeavors to capitalize on scientific breakthroughs that could change our outlook, our health, and our global economy for the better.
Biotech In Action
Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC), among others, have taken the first step in developing a new type of vaccine to protect chickens against coccidiosis, a parasite-caused intestinal disease that affects poultry throughout the world.
A vaccine of this type would be based on proteins from the coccidiosis bug rather than being derived from a live parasite, which means it could be produced on a larger scale than is currently possible, enabling more widespread protection for chicken flocks. Developing protection against animal diseases plays an imperative role in protecting food for human consumption as well.
Professor Douglas Kell, BBSRC CEO, said, "Finding new ways to combat diseases of farmed animals is going to be important to ensure global food security -- but also to the UK economy…This work is a nice example of how studying the fundamental biology of a process at the most minute level could lead to new weapons in the fight against disease."(Excerpt from Science Daily - A Step Towards New Vaccines for Most Important Chicken Parasite.)
Leveraging Innovation To Meet Demand
Rainbow Biosciences is rapidly advancing its initiatives to deliver treatments with the ability to save AND improve the lives of people all over the world. We plan to execute this mission by pursuing additional connections with local academic and industry experts to promote translational and commercially viable research to benefit the human race.
We are currently in discussions to create a potential joint-venture agreement with a privately held drug delivery company working to develop and market a novel sustained-release delivery system. This platform will revolutionize the delivery of biologic agents and small molecules, making them more effective and convenient than with any other delivery method.
This pending deal is complementary to our joint-venture partnership with Nano3D BioSciences (n3D) in which we collaboratively develop and market the Bio-Assembler, a device that utilizes a proprietary process to grow cells in a three-dimensional environment using nanoparticles that produce magnetic fields to lift cells from the bottom of petri dishes. The Bio-Assembler technology has been used to grow heart valves and stem cells, and was recently used to create the first lab-grown lung tissue with organized layers of cells – this incredible achievement shows tremendous promise to advance regenerative medicine! Teaming up with the Houston-based drug delivery company may provide valuable application for the Bio-Assembler.
As we continue to foster new and existing relationships with some of the most promising companies in the biotech industry, we are confident Rainbow Biosciences is poised for explosive growth. We are diligently working to deliver breakthrough treatments to people who need them while delivering huge returns to investors.
Invest today to become a part of this new biotech revolution!
RBCC: Making Biotech Practical
Biosciences are a huge generator of net income across a variety of verticals. Research, testing, medical devices, equipment, pharmaceuticals, and chemicals are seeing tremendous growth as aging populations demand treatment for a number of different illnesses. Other socio-economic issues, such as hunger, may also be addressed by biotech research.
The resulting bioscience technology is an ever-changing, rapidly growing dynamic field of innovation with practical life application, such as the manufacturing of cutting-edge medical devices and the development of new bioscience procedures.
This technology is used to develop novel approaches and medicines in disease treatment, such as synthetically produced therapeutics like the Human Growth Hormone and insulin.
New high-yield, cost-effective production routes are also being researched to produce monoclonal antibodies that have demonstrated an efficacious potential in a number of clinical treatments (Source: Society of Bioscience and Technology).
The sky is the limit for Rainbow Biosciences’ future initiatives – we are backed by a team of scientists dedicated to transitioning leading-edge research into practical, affordable treatments for people who need them.
Investors who stake their claim early in the bioscience market will claim the biggest early returns.
Stock Chart
RBCC In The News
Why Invest In Rainbow Biosciences (OTCBB:RBCC)?
- RBCC in upcoming weeks expects to finalize a strategic partnership with a leading Houston-based genomics company with 11 NASA-licensed patents.
- The company is focused on bringing new deals to investors by year end.
- RBCC is spearheading the most innovative scientific and medical breakthroughs in the $84.6 billion global biotech industry.
- U.S. biotech companies raised $33.4 billion in 2011, up from $25 billion achieved in 2010 and second only to that achieved in 2000 as the genomics bubble reached its peak, according to the latest report from Ernst & Young.
- From the same report, biotech companies in the U.S., Europe, Canada and Australia achieved sales of USD$83.4 billion in 2011, a year-over-year improvement vs. sales in 2010.
- RBCC has retained the investor relations services of QualityStocks, and as a result will be featured in the QualityStocks Newsletter, QualityStocks Daily Blogs, and Message Boards, significantly increasing RBCC’s presence in the trader community.
RBCC: Building The Right Relationships - Increasing Your Bottom Line
Rainbow Biosciences is headquartered in the city of Houston, Texas, which is home to the Texas Medical Center, the world’s largest medical complex. In addition to some of the nation’s top research hospitals and facilities, Houston is home to more than 160 biotechnology companies and academic partnerships.
RBCC has begun to leverage these resources and is delivering the newest and most sought-after biotech innovations to the scientific and medical communities.
Our pending alliances are just a couple of many exciting partnerships that are on the horizon. Bioscience has become the lifeblood of medical and scientific innovation, a hub of economic activity in the global marketplace – and for Rainbow Biosciences, the process of innovation has begun in Houston.
Investing in the biosciences industry and RBCC is more than a just a smart decision-it may be a choice that will lead to wider adoption of treatments that defy the status quo. Invest now to take advantage of this exciting opportunity!